These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35912498)

  • 21. The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group.
    Chan KKW; Cheung MC; Regier DA; Hay A; Louie AV; Cheung WY; Tarride JE; Udayakumar S; Mittmann N
    Curr Oncol; 2021 Sep; 28(5):3649-3658. PubMed ID: 34590616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps.
    Printz C
    Cancer; 2020 Jan; 126(2):239-240. PubMed ID: 31917472
    [No Abstract]   [Full Text] [Related]  

  • 23. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020.
    Bakker E; Starokozhko V; Kraaijvanger JWM; Heerspink HJL; Mol PGM
    Clin Transl Sci; 2023 Nov; 16(11):2394-2412. PubMed ID: 37853917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalised and Precision Medicine in Cancer Clinical Trials: Panacea for Progress or Pandora's Box?
    Lawler M; Sullivan R
    Public Health Genomics; 2015; 18(6):329-37. PubMed ID: 26555236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions.
    Pataky RE; Bryan S; Sadatsafavi M; Peacock S; Regier DA
    Pharmacoeconomics; 2022 Oct; 40(10):931-941. PubMed ID: 35895254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines.
    Ramaekers BL; Joore MA; Grutters JP
    Value Health; 2013; 16(5):855-62. PubMed ID: 23947981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Designing precision medicine trials to yield a greater population impact.
    Zhao YQ; LeBlanc ML
    Biometrics; 2020 Jun; 76(2):643-653. PubMed ID: 31598964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pooled analysis of published, basket trials in cancer medicine.
    Hazim A; Prasad V
    Eur J Cancer; 2018 Sep; 101():244-250. PubMed ID: 30096705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomics of obesity in China: a scoping review.
    Chen Z; Jiang S; Wang Y; Khan MM; Zhang D; Rajbhandari-Thapa J; Li L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):173-181. PubMed ID: 33496208
    [No Abstract]   [Full Text] [Related]  

  • 35. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of inclusion criteria in health economic assessments.
    Richter A; Thieda P; Thaler K; Gartlehner G
    Appl Health Econ Health Policy; 2011 May; 9(3):139-48. PubMed ID: 21506620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using observational data for personalized medicine when clinical trial evidence is limited.
    Gershman B; Guo DP; Dahabreh IJ
    Fertil Steril; 2018 Jun; 109(6):946-951. PubMed ID: 29935652
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.